Filing Flows › Arbutus Biopharma (ABUS) › Q3 2025
Arbutus Biopharma (ABUS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Arbutus Biopharma (ABUS) reported revenue of $529K for the third quarter 2025 (Q3 2025), -60% from a year earlier and -95% from the quarter before.
Arbutus Biopharma, Q3 2025: revenue $529K (-60% year over year), net loss $7.7M, operating cash flow −$5.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $529K | -95% | -60% |
| Operating profit | −$8.7M | -682% | — |
| Net earnings | −$7.7M | -407% | — |
| Operating cash flow | −$5.8M | — | — |
What changed
Revenue was $529K in Q3 2025, down 60% year over year and down 95% from the previous quarter. Collaborations and licenses was the largest line at 53% of revenue. Collaborations and licenses lost $487K year over year (down 63%), 60% of the total change.
Operating costs exceeded revenue by $8.7M, an operating margin of -1636.9%. Total costs fell 60% while revenue fell 60%. The quarter ended with a net loss of $7.7M, after a profit of $2.5M the previous quarter.
Operating cash flow was −$5.8M. Non-cash charges added back $11K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $651K.
Questions
What was Arbutus Biopharma's revenue in the third quarter 2025?
Arbutus Biopharma (ABUS) reported revenue of $529K for the third quarter 2025 (Q3 2025), -60% from a year earlier and -95% from the quarter before.
Source: Arbutus Biopharma 10-Q on SEC EDGAR.